1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exome sequencing of extreme phenotypes to identify variants predictive of response to chemotherapy in bladder cancer
    Meeting Abstract

    Alanee, S.; Shah, S.; Stratton, K. L.; Garcia-Grossman, I. R.; Zabor, E.; Ostrovnaya, I.; Joseph, V.; Pendse, D.; Bajorin, D. F.; Offit, K.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC)
    Meeting Abstract

    Bambury, R. M.; Iyer, G.; Riester, M.; Werner, L.; Schultz, N.; Stack, E. C.; Park, R.; Loda, M.; Ostrovnaya, I.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM)
    Meeting Abstract

    Wen, P. Y.; Yung, W. K. A.; Mellinghoff, I. K.; Lamborn, K.; Ramkissoon, S.; Cloughesy, T. F.; Rinne, M.; Omuro, A. M. P.; DeAngelis, L. M.; Gilbert, M. R.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Genomic heterogeneity of circulating tumor cells in castration-resistant prostate cancer (CRPC) revealed by single-cell sequencing
    Meeting Abstract

    Welsh, A.; Danila, D. C.; Anand, A.; Kendall, J.; Sawyers, C. L.; Fleisher, M.; Wigler, M.; Hicks, J. B.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Chen, Y.; Pham, C. G.; Brannon, A. R.; Scott, S. N.; Takeda, S.; Liu, H.; Motzer, R. J.; Berger, M. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Meeting Abstract

    Sosman, J. A.; Martin-Algarra, S.; Wolchok, J. D.; Sharfman, W. H.; Bhatia, S.; Hodi, F. S.; Hwu, W. J.; Gajewski, T.; Slingluff, C. L.; Kaufman, H.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Next-generation sequencing of genomic and cDNA to identify a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors
    Meeting Abstract

    Stephens, P.; Wiesner, T.; He, J.; Yelensky, R.; Esteve-Puig, R.; Otto, G.; Berger, M. F.; Lipson, D.; Brennan, K.; Miller, V. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save